AGAP3 and cancer: The DepMap analysis showed a significant correlation between AGAP3 expression and cancer cell line sensitivity to vandetanib, and that AGAP3 is overexpressed in more than 98% of the 1,376 cancer cell lines in the database merits further investigation.